BioAge Labs said first-quarter 2026 collaboration revenue rose to $2.8 million from $1.5 million a year earlier, while research and development spending jumped to $20.4 million from $11.1 million and general and administrative expenses increased to $7.7 million from $6.8 million.
The company’s net loss widened to $22.3 million, or $0.52 per share, from $12.9 million, or $0.36 per share, in the same quarter of 2025.
BioAge ended the quarter with about $384.9 million in cash, cash equivalents and marketable securities after completing an upsized follow-on offering that raised roughly $132.3 million in gross proceeds.
On the clinical side, the company reported phase 1 topline data for BGE-102 showing median reductions of 86% in hsCRP across the 60 mg and 120 mg once-daily dose levels. It said 87% to 93% of participants on active treatment reached normalized hsCRP below 2 mg/L, and the drug was well tolerated with no serious adverse events or discontinuations.
BioAge plans to start a phase 2 dose-ranging trial in cardiovascular risk in mid-2026, with data expected by year-end, and a phase 1b/2a study in diabetic macular edema in mid-2026, with results expected in mid-2027.
In R&D, the biggest spending increase came from BGE-102, where direct costs rose by $5.7 million tied to completion of the phase 1 study, trial prep for the next two studies, and drug-product manufacturing. Other programs added $3.6 million in direct costs, while azelaprag costs fell by $0.8 million after development was terminated in January 2025. Today the company's shares have moved 0.45% to a price of $17.90. If you want to know more, read the company's complete 8-K report here.
